Chlorobutanol, a preservative of desmopressin, inhibits human platelet aggregation and release in vitro.

Article Details

Citation
Copy to clipboard

Chen SL, Yang WC, Huang TP, Wann SA, Teng CM

Chlorobutanol, a preservative of desmopressin, inhibits human platelet aggregation and release in vitro.

Thromb Haemost. 1990 Nov 30;64(3):473-7.

PubMed ID
2096493 [ View in PubMed
]
Abstract

Therapeutic preparations of desmopressin for parenteral use contain the preservative chlorobutanol (5 mg/ml). We show here that chlorobutanol is a potent inhibitor of platelet aggregation and release. It exhibited a significant inhibitory activity toward several aggregation inducers in a concentration- and time-dependent manner. Thromboxane B2 formation, ATP release, and elevation of cytosolic free calcium caused by collagen, ADP, epinephrine, arachidonic acid and thrombin respectively were markedly inhibited by chlorobutanol. Chlorobutanol had no effect on elastase-treated platelets and its antiplatelet effect could be reversed. It is concluded that the antiplatelet effect of chlorobutanol is mainly due to its inhibition on the arachidonic acid pathway but it is unlikely to have a nonspecific toxic effect. This antiplatelet effect of chlorobutanol suggests that desmopressin, when administered for improving hemostasis, should not contain chlorobutanol as a preservative.

DrugBank Data that Cites this Article

Drugs